A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer
Abstract Background Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 −) advanced breast cancer is a prevalent subtype among postmenopausal women. Despite the growing number of randomized clinical trials (RCTs) exploring this topic, the efficacy and safety of fi...
Main Authors: | Hanqiao Shao, Mingye Zhao, Ai-Jia Guan, Taihang Shao, Dachuang Zhou, Guo Yu, Wenxi Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12916-023-03238-2 |
Similar Items
-
First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution
by: Guillermo Valencia, et al.
Published: (2024-12-01) -
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis
by: Mingye Zhao, et al.
Published: (2024-02-01) -
Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
by: Junjie Li, et al.
Published: (2019-05-01) -
Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2− Advanced Breast Cancer
by: Xie N, et al.
Published: (2020-06-01) -
The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
by: Xiewei Huang, et al.
Published: (2024-01-01)